VRTX currently shows a PEG ratio reading of 3.67 as of Nov 11, 2026. Dividing the 34.91 PE ratio by the 9.5% earnings growth rate produces this figure. When compared to the trailing 4-quarter average of 1.21, VRTX's PEG ratio reflects a 203% increase.
A ten years lookback reveals an average PEG ratio of 1.32 for Vertex Pharmaceuticals. Compared to historical data, VRTX's 3.67 PEG ratio represents an increase of 178%. The ten years high came in the Mar 2018 quarter at 7.76, reflecting peak valuation relative to growth. The bottom was reached in the Dec 2018 quarter at 0.03, suggesting attractive value relative to growth during that period.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.03 | 29.32 | 843.3% |
| 2024 | N/A | N/A | -114.8% |
| 2023 | 3.49 | 28.96 | 8.3% |
| 2022 | 0.52 | 22.27 | 42.7% |
| 2021 | N/A | 24.16 | -12.9% |
| 2020 | 0.18 | 22.64 | 127.9% |
| 2019 | N/A | 47.81 | -44.4% |
| 2018 | 0.03 | 20.11 | 677.4% |
| 2017 | 0.43 | 141.38 | 330.4% |
| 2016 | N/A | N/A | 80.1% |
| 2015 | N/A | N/A | 26.4% |
| 2014 | N/A | N/A | -58.6% |
| 2013 | N/A | N/A | -296% |
| 2012 | N/A | N/A | -457.1% |
| 2011 | 2.29 | 237.21 | 103.7% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Sep 2026 | 3.51 | 33.36 | 9.5% |
| Jun 2026 | 1.26 | 28.66 | 22.7% |
| Mar 2026 | 0.05 | 26.25 | 545.3% |
| Dec 2025 | 0.03 | 29.32 | 843.3% |
| Sep 2025 | 0.03 | 27.37 | 873.5% |
| Jun 2025 | 0.04 | 31.53 | 847.1% |
| Mar 2025 | N/A | N/A | -124.5% |
| Dec 2024 | N/A | N/A | -114.8% |
| Sep 2024 | N/A | N/A | -113.7% |
| Jun 2024 | N/A | N/A | -114.4% |
| Mar 2024 | 1.19 | 26.83 | 22.6% |
| Dec 2023 | 3.49 | 28.96 | 8.3% |
| Sep 2023 | 4.97 | 25.82 | 5.2% |
| Jun 2023 | 5.38 | 26.88 | 5% |
| Mar 2023 | 0.75 | 24.79 | 32.9% |
VRTX's PEG ratio today sits above the 3, 5 and 10-year averages.
Vertex Pharmaceuticals's PEG of 3.67 is higher than the Healthcare sector and the industry average. Looking at the Healthcare sector average of 0.62, Vertex Pharmaceuticals's PEG is 492% higher.
Relative to its peer stocks ABBV and BMY, VRTX's PEG ratio is higher.
According to Nov 11, 2026 figures, VRTX's PEG ratio stands at 3.67.
VRTX's 3-year PEG ratio average is 1.2.
VRTX's 5-year PEG ratio average is 1.57.
VRTX's PEG ratio topped out at 7.76 during the Mar 2018 quarter - the highest in ten years.
Compared to the 10-year average, VRTX's PEG ratio stands 178% higher.
Slow earnings growth combined with a rich valuation drives VRTX's PEG ratio to 3.67.
To calculate the PEG ratio, take the company's PE ratio and divide by its earnings per share growth (YoY TTM). As of Nov 11, 2026, Vertex Pharmaceuticals has a PE ratio of 34.91. Earnings grew at 9.5% over the TTM period ending Sep 2026. Applying the formula, this gives a PEG ratio of 3.67. PEG RATIO(3.67) = PE RATIO(34.91) / EPS GROWTH(9.5%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.